Here, Jonathan M. Kurie & team show Osi-resistant cancer secrete effector proteins that increase the metastatic properties of drug-naive cells and influence lung cancer progression through paracrine mechanisms:
The figure shows Osi-resistant (OR) cells show Golgi remodeling compared with drug-naïve (DN) cells.
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas–MD Anderson Cancer Center, Houston, Texas, USA.
2Section of Hematology and Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
3Tulane Cancer Center, Louisiana Cancer Research Center, New Orleans, Louisiana, USA.